Phaseline

Companies › Avenue Therapeutics

Avenue Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 10 registered trials: 6 Phase 4, 3 Phase 3, 1 Phase 1; Infectious disease, Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tramadol (AVE-901)
Mu opioid receptor agonist
OPRM1Phase 3Pain Management; Shoulder Arthropathy; Postoperative Pain; Post-surgical Pain …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03774836Tramadol (AVE-901)Phase 3Pain ManagementOtherMay 2019
NCT05488847Tramadol (AVE-901)Phase 4Shoulder ArthropathyOtherDec 2024
NCT06722742Tramadol (AVE-901)Phase 3Shivering, Spinal AnesthesiaInfectious diseaseDec 2024
NCT06742554Tramadol (AVE-901)Phase 4Postoperative PainOtherApr 2025
NCT07060209Tramadol (AVE-901)Phase 1Healthy VolunteersOtherOct 2025
NCT06274333Tramadol (AVE-901)Phase 3Percutaneous Nephrolithotripsy (PCNL)OtherAug 2026
NCT05657704Tramadol (AVE-901)Phase 4Post-surgical PainOtherAug 2026
NCT05657704Tramadol (AVE-901)Phase 4Post-surgical PainOtherAug 2026
NCT05657704Tramadol (AVE-901)Phase 4Post-surgical PainOtherAug 2026
NCT06373978Tramadol (AVE-901)Phase 4Elbow PainOtherJun 2027

From the company's SEC filings

Cash of $2m on 2026-09-30; operating cash outflow about $2m a year; runway about 10 months at that burn, to Aug 2027

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

OPRM1 (1)

Companies with the same targets

Inventage Lab. Trevi Therapeutics Shionogi Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Boulder Care Adneuris Therapeutics Ensysce Biosciences

Companies built like this

Ensysce Biosciences Aligos Therapeutics Invivyd BioVersys SAS Meitheal Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.